STOCK TITAN

MeiraGTx Holdings plc Ordinary Shares - MGTX STOCK NEWS

Welcome to our dedicated page for MeiraGTx Holdings plc Ordinary Shares news (Ticker: MGTX), a resource for investors and traders seeking the latest updates and insights on MeiraGTx Holdings plc Ordinary Shares stock.

MeiraGTx Holdings plc (Nasdaq: MGTX) is a vertically integrated, clinical-stage gene therapy company with a focus on transforming the lives of patients through innovative genetic medicines. Based in London and New York, MeiraGTx pioneers gene therapies for a range of acquired and inherited disorders. The company's research spans serious neurodegenerative diseases such as Alzheimer's, Parkinson's, and ALS, as well as ocular diseases like inherited blindness and age-related macular degeneration. Additionally, MeiraGTx is developing treatments for xerostomia, a debilitating side effect of head and neck cancer radiation therapies.

MeiraGTx's product pipeline includes several advanced-stage clinical trials and preclinical research programs aimed at addressing significant unmet medical needs. Key pipeline products include AAV-CNGB3, AAV-CNGA3, and AAV-RPGR. These therapies target eye disorders, central nervous system conditions, and salivary gland dysfunctions.

The company has gained notable recognition and strategic investments from major pharmaceutical entities. Recently, Sanofi made a $30 million strategic investment in MeiraGTx, validating its Riboswitch gene regulation technology and xerostomia program. This investment underscores the broad potential of MeiraGTx's platform, which supports the development of breakthrough medicines for neurodegenerative and immune-mediated diseases.

MeiraGTx is also advancing its gene therapy manufacturing capabilities, with facilities in the United States, the United Kingdom, and the European Union. The company boasts state-of-the-art viral vector design and optimization, as well as a transformative gene regulation platform technology that allows precise, dose-responsive control of gene expression through oral small molecules.

Financially, MeiraGTx is well-positioned with a robust cash balance, strategic partnerships, and a strong pipeline of potential milestone payments. The company recently reported a $50 million milestone payment from Janssen Pharmaceuticals following the initiation of an extension study for the Phase 3 LUMEOS clinical trial for botaretigene sparoparvovec (bota-vec) for X-linked retinitis pigmentosa.

With a dedicated management team and a comprehensive end-to-end manufacturing infrastructure, MeiraGTx is poised to bring innovative genetic therapies to market, addressing both rare and prevalent diseases. For more information, visit www.meiragtx.com.

Rhea-AI Summary
Sanofi makes a strategic equity investment in Graviton Bioscience, granting a 12-month right of first negotiation to explore collaboration opportunities across various indications, including immunological and metabolic syndrome indications. Graviton Bioscience is focused on therapies that inhibit Rho/Rho-associated coiled-coil containing protein kinase 2 (ROCK2) and other therapeutic compounds. The investment aims to drive the momentum behind ROCK2 inhibitor treatments, which are implicated in the pathology of metabolic, autoimmune, inflammatory, and neurologic disorders with inadequate or no treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.66%
Tags
none
-
Rhea-AI Summary
MeiraGTx Holdings plc (Nasdaq: MGTX) enters into an Asset Purchase Agreement with Janssen Pharmaceuticals, Inc. for the treatment of X-linked retinitis pigmentosa (XLRP) related to botaretigene sparoparvovec (bota-vec), securing up to $415 million. The agreement includes $130 million in upfront and near-term milestone payments, with potential additional revenue from commercial sales and manufacturing technology transfer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
32.59%
Tags
none
-
Rhea-AI Summary
MeiraGTx Holdings plc (MGTX) announced the participation of its President and CEO, Dr. Alexandria Forbes, in two upcoming investor conferences. The live webcasts of the corporate presentations will be available on the Investors page of the company’s website, with replays accessible for approximately 30 days following the presentation dates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.28%
Tags
conferences
Rhea-AI Summary
MeiraGTx Holdings plc (Nasdaq: MGTX) announced a strategic investment from Sanofi, purchasing $30 million of ordinary shares at $7.50 per share. They also announced a right of first negotiation (ROFN) with Sanofi for the use of MeiraGTx’s Riboswitch gene regulation technology for certain CNS and I&I targets, including IL-4 and IL-13, as well as for GLP-1 and other gut peptides for metabolic disease. Enrollment in the Phase 2 study of AAV2-hAQP1 for the treatment of RIX is ongoing. The company presented eight posters at the ESGCT 2023 Annual Congress and received a 2nd Commercial Manufacturer’s/Importer’s Authorization (MIA) for QC testing at their manufacturing facility in Shannon, Ireland.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.33%
Tags
-
Rhea-AI Summary
MeiraGTx Holdings plc announced that Sanofi has made a $30 million strategic investment in the company. Sanofi will purchase 4.0 million ordinary shares at a price of $7.50 per share. Sanofi will also receive a right of first negotiation for the use of MeiraGTx's Riboswitch gene regulation technology for certain Immunology and Inflammation and Central Nervous System targets, as well as for metabolic disease. MeiraGTx is actively pursuing strategic options with other interested parties.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.27%
Tags
none
-
Rhea-AI Summary
MeiraGTx to exhibit eight posters and deliver one oral presentation at the European Society of Gene and Cell Therapy (ESGCT) 2023 Annual Congress. The presentations highlight the depth of innovation in MeiraGTx's technology platforms for gene and cell therapy, particularly in the areas of riboswitch and neurodegenerative programs. The company looks forward to sharing data on its innovative pipeline, manufacturing, and R&D capabilities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.37%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.35%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.65%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.04%
Tags
none

FAQ

What is the current stock price of MeiraGTx Holdings plc Ordinary Shares (MGTX)?

The current stock price of MeiraGTx Holdings plc Ordinary Shares (MGTX) is $6.28 as of December 4, 2024.

What is the market cap of MeiraGTx Holdings plc Ordinary Shares (MGTX)?

The market cap of MeiraGTx Holdings plc Ordinary Shares (MGTX) is approximately 486.1M.

What does MeiraGTx Holdings plc specialize in?

MeiraGTx specializes in developing gene therapies for acquired and inherited disorders, including neurodegenerative and ocular diseases.

Where is MeiraGTx Holdings plc based?

MeiraGTx is based in London, United Kingdom, and New York, United States.

What recent strategic investment did MeiraGTx receive?

MeiraGTx received a $30 million strategic investment from Sanofi.

What are some key products in MeiraGTx's pipeline?

Key products include AAV-CNGB3, AAV-CNGA3, and AAV-RPGR, targeting eye disorders and central nervous system conditions.

What was the recent milestone payment MeiraGTx received?

MeiraGTx received a $50 million milestone payment from Janssen Pharmaceuticals for the Phase 3 LUMEOS clinical trial.

What is MeiraGTx’s Riboswitch gene regulation technology?

It is a technology that allows precise, dose-responsive control of gene expression by oral small molecules, transforming the application of gene therapy.

What diseases is MeiraGTx targeting with its gene therapies?

MeiraGTx targets diseases such as Alzheimer's, Parkinson's, ALS, inherited blindness, age-related macular degeneration, and xerostomia.

What is the significance of the Sanofi investment in MeiraGTx?

Sanofi's investment validates MeiraGTx’s Riboswitch gene regulation technology and xerostomia program, highlighting the broad potential of their platform.

Does MeiraGTx have its own manufacturing facilities?

Yes, MeiraGTx has comprehensive gene therapy manufacturing capabilities in the US, UK, and EU.

Where can I find more information about MeiraGTx's clinical trials?

For more information, visit www.clinicaltrials.gov.

MeiraGTx Holdings plc Ordinary Shares

Nasdaq:MGTX

MGTX Rankings

MGTX Stock Data

486.11M
46.84M
24.25%
55.13%
2.15%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
NEW YORK